Biopharmaceutical Stocks Rise on the 17th... Hanmi Pharmaceutical Up Over 3%, Samsung Epis Holdings, Celltrion, and Samchundang Pharmaceutical Up Over 2%
In the domestic stock market on the 17th, biopharmaceutical-related stocks are showing ups and downs, with gainers holding the upper hand. Hanmi Pharmaceutical is up more than 3%, while Samsung Epis Holdings, Celltrion, and Samchundang Pharmaceutical are rising around 2%. ■ Buying Centered on Large

In the domestic stock market on the 17th, biopharmaceutical-related stocks are showing ups and downs, with gainers holding the upper hand. Hanmi Pharmaceutical is up more than 3%, while Samsung Epis Holdings, Celltrion, and Samchundang Pharmaceutical are rising around 2%.
■ Buying Centered on Large-Cap Stocks... Hanmi Pharmaceutical Up Over 3%
As of the morning of the same day, Hanmi Pharmaceutical is trading at 520,000 won, up 18,000 won (3.59%) from the previous trading day. It opened at 500,000 won and rose to as high as 528,000 won during the session, with a low of 498,500 won. Trading volume is approximately 113,000 shares.
Samsung Epis Holdings is recording 336,500 won, up 9,500 won (2.91%). Its intraday high is 338,000 won, with the current price forming near that high.
Celltrion is trading at 181,900 won, up 4,700 won (2.65%) from the previous session. It opened at 177,100 won and rose to as high as 182,100 won intraday, with a low of 176,900 won.
Samchundang Pharmaceutical is also on the rise at 159,400 won, up 3,300 won (2.11%). It climbed to 160,300 won during the session, moving above the 160,000-won level.
■ Small- and Mid-Cap Stocks Also Strong
PharmGen is up 2.13% at 4,800 won, and Daewoong Pharmaceutical is up 1.93% at 111,000 won. ISU ABXIS is up 1.54% at 3,615 won; Green Cross is up 0.90% at 123,500 won; HanAll BioPharma is up 0.73% at 48,100 won. Celltrion Pharmaceuticals is up 0.64% at 39,050 won, and Aptevo Therapeutics' partner Alteogen (Alteogen) is up 500 won (0.20%) at 256,000 won. Alteogen rose to 260,000 won intraday, with a low of 251,000 won. Aprogen is up 0.20%, and Dong-A ST is up 0.28%.
■ Boryung, SunBio, and Some Others Weak
On the other hand, some stocks are declining. Boryung is down 250 won (2.85%) from the previous session at 8,520 won, a relatively large drop. SunBio is down 2.56% at 5,700 won; Prestige Biologics is down 2.00% at 1,323 won; and LG Chem is down 1.11% at 268,000 won. Bioneer is down 0.79% at 6,290 won; Prestige BioPharma is down 0.34% at 5,930 won; and Chong Kun Dang is down 0.30% at 65,400 won.
■ Why Are Stocks Moving in Different Directions?
In today's biopharmaceutical-related stock movements, the gains in large-cap stocks and some new drug development names stand out. In particular, Hanmi Pharmaceutical is up over 3% while Celltrion and Samsung Epis Holdings are up over 2%, showing buying flows into large-cap biopharmaceutical stocks.
However, it is difficult to view biopharmaceutical stocks as a single uniform business group. Because business structures differ by company—spanning new drug development, biosimilars, biopharmaceutical production, contract development and manufacturing (CDMO), and drug delivery platforms—stock price directions and magnitudes of gains can diverge significantly even on the same day.
Looking only at intraday trends, Hanmi Pharmaceutical is relatively strong with a gain of over 3%, followed by Samsung Epis Holdings, Celltrion, and Samchundang Pharmaceutical, while Boryung, SunBio, and Prestige Biologics are showing weakness—a differentiated phase.
Biopharmaceutical companies can see expanded stock price volatility depending on clinical trials, regulatory approvals, technology transfers, and the results of R&D and production/supply contracts, and actual business stages and revenue contributions vary by company. This article is not a recommendation to invest in any specific stock, and the final judgment on investments and the responsibility for them rest with the investor. This article was partially assisted by AI in the writing process.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


